Key statistics
On Wednesday, INmune Bio Inc (0Y2:BER) closed at 4.68, 8.84% above its 52-week low of 4.30, set on Sep 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.84 |
---|---|
High | 4.84 |
Low | 4.38 |
Bid | 4.38 |
Offer | 5.15 |
Previous close | 4.82 |
Average volume | 0.00 |
---|---|
Shares outstanding | 22.17m |
Free float | 15.80m |
P/E (TTM) | -- |
Market cap | 117.74m USD |
EPS (TTM) | -2.06 USD |
Data delayed at least 15 minutes, as of Oct 09 2024 20:52 BST.
More ▼
Announcements
- INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease
- INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort
- INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints
- INmune Bio Announces $13.0 Million Registered Direct Offering
- INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference
- INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients
- INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024
- INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer
- INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial
- INmune Bio Inc. to Join Russell 3000® Index
More ▼